Literature DB >> 17070774

Expression and distribution of Gpr119 in the pancreatic islets of mice and rats: predominant localization in pancreatic polypeptide-secreting PP-cells.

Yukiko Sakamoto1, Hiroshi Inoue, Shuhei Kawakami, Katsuyuki Miyawaki, Tatsuro Miyamoto, Kuniko Mizuta, Mitsuo Itakura.   

Abstract

The GPR119 was recently shown to be activated by oleoylethanolamide (OEA), a naturally occurring bioactive lipid with hypophagic and anti-obesity effects. In this study, we have cloned and characterized its murine counterpart, Gpr119. The full-length cDNA contained an open reading frame of 1008bp encoding a 335-amino acid protein. The genomic organization of Gpr119 was unique, having a 3'-untranslated second exon that was also involved in an alternative splicing event. Gene expression analyses confirmed its specific expressions in pancreatic islets and two endocrine cell-lines, MIN6 and alphaTC1. Immunohistochemistry and double-immunofluorescence studies using a specific antibody revealed the predominant Gpr119 localization in pancreatic polypeptide (PP)-cells of islets. No definitive evidence of Gpr119-immunoreactivity in adult beta- or alpha-cells was obtained. The Gpr119 mRNA levels were elevated in islets of obese hyperglycemic db/db mice as compared to control islets, suggesting a possible involvement of this receptor in the development of obesity and diabetes.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 17070774     DOI: 10.1016/j.bbrc.2006.10.076

Source DB:  PubMed          Journal:  Biochem Biophys Res Commun        ISSN: 0006-291X            Impact factor:   3.575


  24 in total

1.  Design of Potent and Orally Active GPR119 Agonists for the Treatment of Type II Diabetes.

Authors:  Ping Liu; Zhiyong Hu; Byron G DuBois; Christopher R Moyes; David N Hunter; Cheng Zhu; Nam Fung Kar; Yuping Zhu; Joie Garfunkle; Ling Kang; Gary Chicchi; Anka Ehrhardt; Andrea Woods; Toru Seo; Morgan Woods; Margaret van Heek; Karen H Dingley; Jianmei Pang; Gino M Salituro; Joyce Powell; Jenna L Terebetski; Viktor Hornak; Louis-Charles Campeau; Joe Lamberson; Fez Ujjainwalla; Michael Miller; Andrew Stamford; Harold B Wood; Timothy Kowalski; Ravi P Nargund; Scott D Edmondson
Journal:  ACS Med Chem Lett       Date:  2015-07-10       Impact factor: 4.345

2.  Discovery and characterization of novel small molecule agonists of G protein-coupled receptor 119.

Authors:  Shu-yong Zhang; Jing Li; Xin Xie
Journal:  Acta Pharmacol Sin       Date:  2014-03-31       Impact factor: 6.150

3.  G protein-coupled receptors and insulin secretion: 119 and counting.

Authors:  S R Murthy Madiraju; Vincent Poitout
Journal:  Endocrinology       Date:  2007-06       Impact factor: 4.736

4.  Gastrointestinal hormonal responses on GPR119 activation in lean and diseased rodent models of type 2 diabetes.

Authors:  S Patel; O J Mace; I R Tough; J White; T-A Cock; U Warpman Berglund; M Schindler; H M Cox
Journal:  Int J Obes (Lond)       Date:  2014-01-23       Impact factor: 5.095

Review 5.  Peripheral neural targets in obesity.

Authors:  Amanda J Page; Erin Symonds; Madusha Peiris; L Ashley Blackshaw; Richard L Young
Journal:  Br J Pharmacol       Date:  2012-07       Impact factor: 8.739

6.  Structural basis for constitutive activity and agonist-induced activation of the enteroendocrine fat sensor GPR119.

Authors:  M S Engelstoft; C Norn; M Hauge; N D Holliday; L Elster; J Lehmann; R M Jones; T M Frimurer; T W Schwartz
Journal:  Br J Pharmacol       Date:  2014-12       Impact factor: 8.739

Review 7.  Receptors for acylethanolamides-GPR55 and GPR119.

Authors:  Grzegorz Godlewski; László Offertáler; Jens A Wagner; George Kunos
Journal:  Prostaglandins Other Lipid Mediat       Date:  2009-07-15       Impact factor: 3.072

Review 8.  Biological functions and metabolism of oleoylethanolamide.

Authors:  Clémentine Thabuis; Delphine Tissot-Favre; Jean-Baptiste Bezelgues; Jean-Charles Martin; Cristina Cruz-Hernandez; Fabiola Dionisi; Frédéric Destaillats
Journal:  Lipids       Date:  2008-08-13       Impact factor: 1.880

Review 9.  Non-CB1, non-CB2 receptors for endocannabinoids, plant cannabinoids, and synthetic cannabimimetics: focus on G-protein-coupled receptors and transient receptor potential channels.

Authors:  Luciano De Petrocellis; Vincenzo Di Marzo
Journal:  J Neuroimmune Pharmacol       Date:  2009-10-22       Impact factor: 4.147

Review 10.  GPR119, a novel G protein-coupled receptor target for the treatment of type 2 diabetes and obesity.

Authors:  H A Overton; M C T Fyfe; C Reynet
Journal:  Br J Pharmacol       Date:  2007-11-26       Impact factor: 8.739

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.